Reuter U, et al. Long-term efficacy and safety of erenumab: Results from 64 weeks of the LIBERTY study. IHC-OR-006. IHC 2019 5-8 sept. Dublin, Ierland.
Cognitieve revalidatie en mindfulness verminderen cognitieve klachten bij MS
mrt 2023 | Multipele Sclerose